Cable Car Capital LP acquired a new position in shares of Curis, Inc. (NASDAQ:CRIS – Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 1,333,334 shares of the biotechnology company’s stock, valued at approximately $696,000. Cable Car Capital LP owned about 0.64% of Curis at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC grew its holdings in Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Curis by 71.8% in the fourth quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Curis in the fourth quarter valued at $26,000. Maverick Capital Ltd. lifted its position in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after acquiring an additional 49,554 shares in the last quarter. Finally, Focused Wealth Management Inc boosted its stake in shares of Curis by 83.4% during the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 49,900 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.
Curis Stock Up 0.6%
CRIS stock opened at $1.59 on Wednesday. Curis, Inc. has a 52-week low of $1.50 and a 52-week high of $39.00. The stock’s fifty day simple moving average is $4.87 and its 200-day simple moving average is $10.88. The stock has a market capitalization of $3.32 million, a price-to-earnings ratio of -0.11 and a beta of 3.13.
Analyst Ratings Changes
A number of research firms recently commented on CRIS. HC Wainwright reiterated a “buy” rating on shares of Curis in a research report on Monday, August 17th. Zacks Research lowered shares of Curis from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 11th. Wall Street Zen upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $43.00.
View Our Latest Stock Analysis on CRIS
Curis Company Profile
Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.
Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.
See Also
- Five stocks we like better than Curis
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS – Free Report).
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
